” Drugs are not even made with Africans in mind, they are not trialled clinically with an African population, so what you have is drugs with lower efficacy for African populations and with poorer security profiles,” he told the BBC.
New drugs also take time to reach Africa – often in between 15 and 20 years, says Dr Ene-Obong.
Pharmaceutical giants typically make drugs for the rewarding Western market, and the generic variants are only offered in Africa after these companies lose their patents.
Dr Ene-Obong states the method to fix this lag is to increase access to genomic data from African populations to promote inclusive scientific research study.
” This will lead to optimised treatment and diagnostic results that will not only deal with Africans however likewise everybody else,” he states.
However Dr Ene-Obong states 54 gene will also explore the genetic function in non-communicable illness like cancer, cardio-vascular illness, hypertension, dementia and others.
He says the company is not simply interested in collecting samples and saving them in a biobank but also enhancing health care in the communities where they work.
I see it as reverse brain drain, a sort of brain gain, bringing together talented people who have actually worked in locations where they offer world class medical care”
Dr Ene-Obong left his role as a management expert in the pharmaceutical sector to start 54 gene, which is currently made up of more than 30 researchers who have operated in leading medical organizations in the US and UK.
” I see it as reverse brain drain, a sort of brain gain, bringing together talented people who have operated in locations where they offer world class medical care.
” Our objective is to ensure that people are being detected and dealt with utilizing comparable standards of care that you’ll find in the UK or the US,” he states.
The biotech company – called after the 54 globally identified countries in Africa – likewise prepares to broaden operations on the continent through partnerships with pharmaceuticals and research programs on the continent.
” We are not trying simply to be a Nigerian business … we remain in talks with nations in East Africa, West Africa and South Africa.”
However, he is stressed over guidelines or the absence of them in some African nations.
” We are abiding by the needed laws, however as you know often there are guidelines that are uncertain. We are constantly on alert so that we are certified with all the essential laws.”
The business has actually registered to comply with data protection guidelines like the United States Health Insurance Mobility and Responsibility (Hipa) laws and Europe’s General Data Security Guideline (GDPR) policy.
He states that all patient information is anonymised and kept in encrypted systems.
Companies developing drugs or diagnostic tests pay 54 gene for collecting, anonymising and aggregating hereditary information, Dr Ene-Obong says of the company’s service technique.
Getty Images Image caption
The company prepares to introduce several labs throughout the continent.
There are several federal governments in Africa, for instance in Kenya and Uganda, where the authorities have actually proposed the mass collection of DNA information to assist battle criminal offense.
The data collected by 54 gene could for that reason be valuable to the government and other personal organisations.
However Dr Ene-Obong states the company has no interest in sharing the details they gather.
” We have actually been approached by insurance companies to see if they can use the information to modify their offerings however we have turned those down.”
The company would, nevertheless, be willing to share “broad view information”, which might assist the government in comprehending the status of the health of their populations.
” Info that they can use for planning and resource allowance,” he discusses.
He says 54 gene is identified not just to be regarded as “an African company” but a biotech company with international footing.